肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 JTA意见书：成人低危甲状腺乳头状微小癌(T1aN0M0)患者的管理

2021-03-23 日本甲状腺协会 Endocr J . 2021 Mar 23. doi: 10.1507/endocrj.EJ20-0692.

甲状腺乳头状癌

2021年3月，日本甲状腺协会(JTA)发布了成人低危甲状腺乳头状微小癌(T1aN0M0)患者的管理意见书。甲状腺癌的发病率在世界范围内呈上升趋势，因为甲状腺乳头状微小癌（PTMC）的偶然发现增加。本

中文标题：

2021 JTA意见书：成人低危甲状腺乳头状微小癌(T1aN0M0)患者的管理

英文标题：

Position paper from the Japan Thyroid Association task force on the management of low-risk papillary thyroid microcarcinoma (T1aN0M0) in adults

发布机构：

日本甲状腺协会

发布日期：

2021-03-23

简要介绍：

2021年3月，日本甲状腺协会(JTA)发布了成人低危甲状腺乳头状微小癌(T1aN0M0)患者的管理意见书。甲状腺癌的发病率在世界范围内呈上升趋势，因为甲状腺乳头状微小癌（PTMC）的偶然发现增加。本文提出了甲状腺乳头状微小癌发病率增加的证据并针对该类患者的管理提供指导。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 JTA意见书：成人低危甲状腺乳头状微小癌(T1aN0M0)患者的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=8f5871c0020e7ab1, title=2021 JTA意见书：成人低危甲状腺乳头状微小癌(T1aN0M0)患者的管理, enTitle=Position paper from the Japan Thyroid Association task force on the management of low-risk papillary thyroid microcarcinoma (T1aN0M0) in adults, guiderFrom=Endocr J . 2021 Mar 23. doi: 10.1507/endocrj.EJ20-0692., authorId=0, author=, summary=2021年3月，日本甲状腺协会(JTA)发布了成人低危甲状腺乳头状微小癌(T1aN0M0)患者的管理意见书。甲状腺癌的发病率在世界范围内呈上升趋势，因为甲状腺乳头状微小癌（PTMC）的偶然发现增加。本, cover=https://img.medsci.cn/2021330/1617118218953_2020535.jpg, journalId=0, articlesId=null, associationId=1316, associationName=日本甲状腺协会, associationIntro=, copyright=0, guiderPublishedTime=Tue Mar 23 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年3月，日本甲状腺协会(JTA)发布了成人低危甲状腺乳头状微小癌(T1aN0M0)患者的管理意见书。甲状腺癌的发病率在世界范围内呈上升趋势，因为甲状腺乳头状微小癌（PTMC）的偶然发现增加。本文提出了甲状腺乳头状微小癌发病率增加的证据并针对该类患者的管理提供指导。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=888, tagName=甲状腺乳头状癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=23, categoryName=普通外科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=888, guiderKeyword=甲状腺乳头状癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=18477, appHits=193, showAppHits=0, pcHits=1637, showPcHits=18284, likes=1, shares=10, comments=13, approvalStatus=1, publishedTime=Tue Mar 30 23:50:47 CST 2021, publishedTimeString=2021-03-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Mar 30 23:32:59 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 07:01:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 JTA意见书：成人低危甲状腺乳头状微小癌(T1aN0M0)患者的管理.pdf)])
2021 JTA意见书：成人低危甲状腺乳头状微小癌(T1aN0M0)患者的管理.pdf
下载请点击：
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1247620, encodeId=49e7124e620c0, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4025395732, createdName=ms6000001056789392, createdTime=Wed Sep 07 08:28:39 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184429, encodeId=0fcf11844297d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02972000979, createdName=walking, createdTime=Fri Jan 14 23:49:06 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085303, encodeId=d6aa1085303d8, content=非常及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Wed Dec 29 07:30:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067859, encodeId=4f33106e8599f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:55:28 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067857, encodeId=13a7106e85747, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:53:37 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2022-09-07 ms6000001056789392

    好资料

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1247620, encodeId=49e7124e620c0, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4025395732, createdName=ms6000001056789392, createdTime=Wed Sep 07 08:28:39 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184429, encodeId=0fcf11844297d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02972000979, createdName=walking, createdTime=Fri Jan 14 23:49:06 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085303, encodeId=d6aa1085303d8, content=非常及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Wed Dec 29 07:30:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067859, encodeId=4f33106e8599f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:55:28 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067857, encodeId=13a7106e85747, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:53:37 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2022-01-14 walking

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1247620, encodeId=49e7124e620c0, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4025395732, createdName=ms6000001056789392, createdTime=Wed Sep 07 08:28:39 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184429, encodeId=0fcf11844297d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02972000979, createdName=walking, createdTime=Fri Jan 14 23:49:06 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085303, encodeId=d6aa1085303d8, content=非常及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Wed Dec 29 07:30:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067859, encodeId=4f33106e8599f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:55:28 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067857, encodeId=13a7106e85747, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:53:37 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2021-12-29 豪杰克

    非常及时

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1247620, encodeId=49e7124e620c0, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4025395732, createdName=ms6000001056789392, createdTime=Wed Sep 07 08:28:39 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184429, encodeId=0fcf11844297d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02972000979, createdName=walking, createdTime=Fri Jan 14 23:49:06 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085303, encodeId=d6aa1085303d8, content=非常及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Wed Dec 29 07:30:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067859, encodeId=4f33106e8599f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:55:28 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067857, encodeId=13a7106e85747, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:53:37 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2021-11-07 1471d48dm72暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1247620, encodeId=49e7124e620c0, content=好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4025395732, createdName=ms6000001056789392, createdTime=Wed Sep 07 08:28:39 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184429, encodeId=0fcf11844297d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02972000979, createdName=walking, createdTime=Fri Jan 14 23:49:06 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085303, encodeId=d6aa1085303d8, content=非常及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210526/d8036608a81e44d183c185e06517e1cf/fd173bc0aba64070b54b049cedcc6bce.jpg, createdBy=41cf5507885, createdName=豪杰克, createdTime=Wed Dec 29 07:30:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067859, encodeId=4f33106e8599f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:55:28 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067857, encodeId=13a7106e85747, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Sun Nov 07 17:53:37 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2021-11-07 1471d48dm72暂无昵称

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

拓展阅读

甲状腺结节超声恶性危险分层中国指南（C-TIRADS）对甲状腺乳头状癌的诊断价值

联勤保障部队第九〇九医院(厦门大学附属东南医院)超声诊断科 · 2022-07-29